To study the role of anti H pylori drugs in treating patients who are H pylori positive and suffering with non-ulcer dyspepsia.
- Conditions
- Health Condition 1: K30- Functional dyspepsia
- Registration Number
- CTRI/2021/02/031445
- Lead Sponsor
- Dr VIVEK BHAVANAM
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 73
Rome IV Criteria
One or more of the following:
1. Bothersome postprandial fullness
2. Bothersome early satiation
3. Bothersome epigastric pain
4. Bothersome epigastric burning
AND
No evidence of structural disease(including at upper GI endoscopy) that is likely to explain the symptoms.
Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis.
1. Any evidence of organic (pancreatobiliary disease, oesophagitis, peptic ulcer disease and neoplastic disease), drug-induced (non steroidal anti-inflammatory drugs), endocrine and metabolic disorders diagnosed by appropriate investigations.
2. Symptoms that are relieved by evacuation of feces or gas
3. Persistent vomiting
4. Biliary pain
5. Any erosion/ulcer in upper GI endoscopy
6. Pregnant women
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Dyspeptic symptoms assessment with the help of standard dyspeptic scores before and after completion of anti H pylori therapyTimepoint: 1 month(for completion of anti H pylori therapy)
- Secondary Outcome Measures
Name Time Method The status of the patients for H pylori (positive or negative) after receiving anti H pylori therapy.Timepoint: 15 days after completion of the treatment course (to obtain the HPE report)